Upregulation of lnc-FOXD2-AS1, CDC45, and CDK1 in patients with primary non-M3 AML is associated with a worse prognosis.
Acute myeloid leukemia
Bioinformatics
CDC20 and CCNB1
CDC45
CDK1
Lnc -FOXD2-AS1
Journal
Blood research
ISSN: 2287-979X
Titre abrégé: Blood Res
Pays: Switzerland
ID NLM: 101605247
Informations de publication
Date de publication:
19 Feb 2024
19 Feb 2024
Historique:
received:
12
09
2023
accepted:
03
01
2024
medline:
15
3
2024
pubmed:
15
3
2024
entrez:
15
3
2024
Statut:
epublish
Résumé
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy with an unfavorable outcome. The present research aimed to identify novel biological targets for AML diagnosis and treatment. In this study, we performed an in-silico method to identify antisense RNAs (AS-RNAs) and their related co-expression genes. GSE68172 was selected from the AML database of the Gene Expression Omnibus and compared using the GEO2R tool to find DEGs. Antisense RNAs were selected from all the genes that had significant expression and a survival plot was drawn for them in the GEPIA database, FOXD2-AS1 was chosen for further investigation based on predetermined criteria (logFC ≥|1| and P < 0.05) and its noteworthy association between elevated expression level and a marked reduction in the overall survival (OS) in patients diagnosed with AML. The GEPIA database was utilized to investigate FOXD2-AS1-related co-expression and similar genes. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis and gene ontology (GO) function analysis of the mentioned gene lists were performed using the DAVID database. The protein-protein interaction (PPI) network was then constructed using the STRING database. Hub genes were screened using Cytoscape software. Pearson correlation analysis was conducted using the GEPIA database to explore the relationship between FOXD2-AS1 and the hub genes. The transcription of the selected coding and non-coding genes, including FOXD2-AS1, CDC45, CDC20, CDK1, and CCNB1, was validated in 150 samples, including 100 primary AML non-M3 blood samples and 50 granulocyte colony stimulating factor (G-CSF)-mobilized healthy donors, using quantitative Real-Time PCR (qRT-PCR). qRT-PCR results displayed significant upregulation of lnc-FOXD2-AS1, CDC45, and CDK1 in primary AML non-M3 blood samples compared to healthy blood samples (P = 0.0032, P = 0.0078, and P = 0.0117, respectively). The expression levels of CDC20 and CCNB1 were not statistically different between the two sets of samples (P = 0.8315 and P = 0.2788, respectively). We identified that AML patients with upregulation of FOXD2-AS1, CDK1, and CDC45 had shorter overall survival (OS) and Relapse-free survival (RFS) compared those with low expression of FOXD2-AS1, CDK1, and CDC45. Furthermore, the receiver operating characteristic (ROC) curve showed the potential biomarkers of lnc -FOXD2-AS1, CDC45, and CDK1 in primary AML non-M3 blood samples. This research proposed that the dysregulation of lnc-FOXD2-AS1, CDC45, and CDK1 can contribute to both disease state and diagnosis as well as treatment. The present study proposes the future evolution of the functional role of lnc-FOXD2-AS1, CDC45, and CDK1 in AML development.
Identifiants
pubmed: 38485838
doi: 10.1007/s44313-024-00002-0
pii: 10.1007/s44313-024-00002-0
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4Informations de copyright
© 2024. The Author(s).
Références
Pashaiefar H, Izadifard M, Yaghmaie M, et al. Low expression of long noncoding RNA IRAIN is associated with poor prognosis in non-M3 acute myeloid leukemia patients. Genet Test Mol Biomarkers. 2018;22:288–94.
doi: 10.1089/gtmb.2017.0281
pubmed: 29634410
Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013;381:484–95.
doi: 10.1016/S0140-6736(12)61727-9
pubmed: 23399072
Antar AI, Otrock ZK, Abou Dalle I, El-Cheikh J, Bazarbachi A. Pharmacologic therapies to prevent relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Front Oncol. 2020;10:596134.
doi: 10.3389/fonc.2020.596134
pubmed: 33224890
pmcid: 7667262
Mosquera Orgueira A, Peleteiro Raíndo A, Cid López M, et al. Personalized survival prediction of patients with acute myeloblastic leukemia using gene expression profiling. Front Oncol. 2021;11:657191.
doi: 10.3389/fonc.2021.657191
pubmed: 33854980
pmcid: 8040929
Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood. 2007;109:874–85.
doi: 10.1182/blood-2006-07-012252
pubmed: 17008539
Yang L, Zhang H, Yang X, et al. Prognostic prediction of cytogenetically normal acute myeloid leukemia based on a gene expression model. Front Oncol. 2021;11:659201.
doi: 10.3389/fonc.2021.659201
pubmed: 34123815
pmcid: 8190396
Li P, Zhong X, Zhang L, Yu Y, Niu J. Bioinformatic investigation for candidate genes and molecular mechanism in the pathogenesis of membranous nephropathy. Nephrology (Carlton). 2021;26:262–9.
doi: 10.1111/nep.13833
pubmed: 33207024
Tinker AV, Boussioutas A, Bowtell DD. The challenges of gene expression microarrays for the study of human cancer. Cancer Cell. 2006;9:333–9.
doi: 10.1016/j.ccr.2006.05.001
pubmed: 16697954
Hedblom A, Laursen KB, Miftakhova R, et al. CDK1 interacts with RARγ and plays an important role in treatment response of acute myeloid leukemia. Cell Cycle. 2013;12:1251–66.
doi: 10.4161/cc.24313
pubmed: 23518499
pmcid: 3674090
Aleem E, Arceci RJ. Targeting cell cycle regulators in hematologic malignancies. Front Cell Dev Biol. 2015;3:16.
doi: 10.3389/fcell.2015.00016
pubmed: 25914884
pmcid: 4390903
Weinberg OK, Sohani AR, Bhargava P, Nardi V. Diagnostic work-up of acute myeloid leukemia. Am J Hematol. 2017;92:317–21.
doi: 10.1002/ajh.24648
pubmed: 28066929
de Jonge HJ, Huls G, de Bont ES. Gene expression profiling in acute myeloid leukaemia. Neth J Med. 2011;69:167–76.
pubmed: 21527803
Tao Z, Shi A, Li R, Wang Y, Wang X, Zhao J. Microarray bioinformatics in cancer- a review. J BUON. 2017;22:838–43.
pubmed: 29155508
Morlando M, Ballarino M, Fatica A. Long non-coding RNAs: new players in hematopoiesis and leukemia. Front Med (Lausanne). 2015;2:23.
pubmed: 25927065
Babashah S, Sadeghizadeh M, Tavirani MR, Farivar S, Soleimani M. Aberrant microRNA expression and its implications in the pathogenesis of leukemias. Cell Oncol (Dordr). 2012;35:317–34.
doi: 10.1007/s13402-012-0095-3
pubmed: 22956261
Hu Q, Tai S, Wang J. Oncogenicity of lncRNA FOXD2-AS1 and its molecular mechanisms in human cancers. Pathol Res Pract. 2019;215:843–8.
doi: 10.1016/j.prp.2019.01.033
pubmed: 30723052
Xu TP, Wang WY, Ma P, et al. Upregulation of the long noncoding RNA FOXD2-AS1 promotes carcinogenesis by epigenetically silencing EphB3 through EZH2 and LSD1, and predicts poor prognosis in gastric cancer. Oncogene. 2018;37:5020–36.
doi: 10.1038/s41388-018-0308-y
pubmed: 29789713
Liu X, Fu Q, Li S, et al. LncRNA FOXD2-AS1 functions as a competing endogenous RNA to regulate TERT expression by sponging miR-7-5p in thyroid cancer. Front Endocrinol (Lausanne). 2019;10:207.
doi: 10.3389/fendo.2019.00207
pubmed: 31024447
Zhu Y, Qiao L, Zhou Y, Ma N, Wang C, Zhou J. Long non-coding RNA FOXD 2-AS 1 contributes to colorectal cancer proliferation through its interaction with micro RNA-185-5p. Cancer Sci. 2018;109:2235–42.
doi: 10.1111/cas.13632
pubmed: 29737580
pmcid: 6029818
Chen G, Sun W, Hua X, Zeng W, Yang L. Long non-coding RNA FOXD2-AS1 aggravates nasopharyngeal carcinoma carcinogenesis by modulating miR-363-5p/S100A1 pathway. Gene. 2018;645:76–84.
doi: 10.1016/j.gene.2017.12.026
pubmed: 29248577
Zhang Y, Hu J, Zhou W, Gao H. LncRNA FOXD2-AS1 accelerates the papillary thyroid cancer progression through regulating the miR-485-5p/KLK7 axis. J Cell Biochem. 2019;120:7952–61.
doi: 10.1002/jcb.28072
pubmed: 30456805
Xu Y, Yu X, Sun Z, He Y, Guo W. Roles of lncRNAs mediating Wnt/β-catenin signaling in HCC. Front Oncol. 2022;12:831366.
doi: 10.3389/fonc.2022.831366
pubmed: 35356220
pmcid: 8959654
Jones MC, Askari JA, Humphries JD, Humphries MJ. Cell adhesion is regulated by CDK1 during the cell cycle. J Cell Biol. 2018;217:3203–18.
doi: 10.1083/jcb.201802088
pubmed: 29930204
pmcid: 6122981
Shi Q, Zhou Z, Ye N, Chen Q, Zheng X, Fang M. MiR-181a inhibits non-small cell lung cancer cell proliferation by targeting CDK1. Cancer Biomark. 2017;20:539–46.
doi: 10.3233/CBM-170350
pubmed: 28946554
Sung WW, Lin YM, Wu PR, et al. High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients. BMC Cancer. 2014;14:951.
doi: 10.1186/1471-2407-14-951
pubmed: 25511643
pmcid: 4302138
Li Y, Chen YL, Xie YT, et al. Association study of germline variants in CCNB1 and CDK1 with breast cancer susceptibility, progression, and survival among Chinese Han women. PLoS ONE. 2013;8:e84489.
doi: 10.1371/journal.pone.0084489
pubmed: 24386390
pmcid: 3873991
Xi Q, Huang M, Wang Y, et al. The expression of CDK1 is associated with proliferation and can be a prognostic factor in epithelial ovarian cancer. Tumour Biol. 2015;36:4939–48.
doi: 10.1007/s13277-015-3141-8
pubmed: 25910705
Sofi S, Mehraj U, Qayoom H, et al. Targeting cyclin-dependent kinase 1 (CDK1) in cancer: molecular docking and dynamic simulations of potential CDK1 inhibitors. Med Oncol. 2022;39:133.
doi: 10.1007/s12032-022-01748-2
pubmed: 35723742
pmcid: 9207877
Qian Z, Fernald AA, Godley LA, Larson RA, Le Beau MM. Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc Natl Acad Sci U S A. 2002;99:14925–30.
doi: 10.1073/pnas.222491799
pubmed: 12417757
pmcid: 137521
Everett JA. The 12 item Social and Economic Conservatism Scale (SECS). PLoS ONE. 2013;8:e82131.
doi: 10.1371/journal.pone.0082131
pubmed: 24349200
pmcid: 3859575
Zeestraten EC, Maak M, Shibayama M, et al. Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer. Br J Cancer. 2012;106:133–40.
doi: 10.1038/bjc.2011.504
pubmed: 22108518
Radomska HS, Alberich-Jordà M, Will B, Gonzalez D, Delwel R, Tenen DG. Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα. J Clin Invest. 2012;122:2955–66.
doi: 10.1172/JCI43354
pubmed: 22797303
pmcid: 3408728
Liu L, Zhang Y, Zhang J, et al. Characterization of the dimeric CMG/pre-initiation complex and its transition into DNA replication forks. Cell Mol Life Sci. 2020;77:3041–58.
doi: 10.1007/s00018-019-03333-9
pubmed: 31728581
Yang C, Xie S, Wu Y, et al. Prognostic implications of CDC45 expression in hepatocellular carcinoma. PeerJ. 2021;9:e10824.
doi: 10.7717/peerj.10824
pubmed: 33614286
pmcid: 7883691
Wu J, Lv Q, Huang H, Zhu M, Meng D. Screening and identification of key biomarkers in inflammatory breast cancer through integrated bioinformatic analyses. Genet Test Mol Biomarkers. 2020;24:484–91.
doi: 10.1089/gtmb.2020.0047
pubmed: 32598242
Hu Y, Wang L, Li Z, et al. Potential prognostic and diagnostic values of CDC6, CDC45, ORC6 and SNHG7 in colorectal cancer. Onco Targets Ther. 2019;12:11609–21.
doi: 10.2147/OTT.S231941
pubmed: 32021241
pmcid: 6942537
Perl AL, O’Connor CM, Fa P, et al. Protein phosphatase 2A controls ongoing DNA replication by binding to and regulating cell division cycle 45 (CDC45). J Biol Chem. 2019;294:17043–59.
doi: 10.1074/jbc.RA119.010432
pubmed: 31562245
pmcid: 6851307
Edwards MC, Tutter AV, Cvetic C, Gilbert CH, Prokhorova TA, Walter JC. MCM2-7 complexes bind chromatin in a distributed pattern surrounding the origin recognition complex in Xenopus egg extracts. J Biol Chem. 2002;277:33049–57.
doi: 10.1074/jbc.M204438200
pubmed: 12087101
Huang J, Li Y, Lu Z, et al. Analysis of functional hub genes identifies CDC45 as an oncogene in non-small cell lung cancer-a short report. Cell Oncol (Dordr). 2019;42:571–8.
doi: 10.1007/s13402-019-00438-y
pubmed: 30887286
Yang S, Ren X, Liang Y, et al. KNK437 restricts the growth and metastasis of colorectal cancer via targeting DNAJA1/CDC45 axis. Oncogene. 2020;39:249–61.
doi: 10.1038/s41388-019-0978-0
pubmed: 31477839